Title : CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.

Pub. Date : 2015

PMID : 26037375






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This article reviews the contribution of genetic polymorphisms affecting the activity of CYP2C9, the main enzyme responsible for phenytoin metabolism, to the variation in phenytoin clearance and susceptibility to adverse effects. Phenytoin cytochrome P450 family 2 subfamily C member 9 Homo sapiens
2 This article reviews the contribution of genetic polymorphisms affecting the activity of CYP2C9, the main enzyme responsible for phenytoin metabolism, to the variation in phenytoin clearance and susceptibility to adverse effects. Phenytoin cytochrome P450 family 2 subfamily C member 9 Homo sapiens
3 AREAS COVERED: Comprehensive and critical review of available evidence concerning the influence of CYP2C9 genetic polymorphism on phenytoin pharmacokinetic and safety profile. Phenytoin cytochrome P450 family 2 subfamily C member 9 Homo sapiens
4 EXPERT OPINION: There is extensive evidence that CYP2C9 polymorphisms are an important determinant of the rate of phenytoin metabolism, although other factors including expression of other enzymes such as CYP2C19 and the influence of drug interactions, physiological and disease-related factors may also play a role. Phenytoin cytochrome P450 family 2 subfamily C member 9 Homo sapiens
5 The clinical value and cost-effectiveness of CYP2C9 genotyping in improving the safety of phenytoin therapy, however, have not been clearly established and require formal testing in well-designed prospective studies. Phenytoin cytochrome P450 family 2 subfamily C member 9 Homo sapiens